Germany
Japan
United Kingdom
China
Aggrecan (ACAN) mouse monoclonal antibody, clone HAG7D4 (7D4), Purified
| Applications | ELISA, IHC, IP, WB |
| Reactivities | Bovine, Human |
Primary Antibodies
Glycophorin A (GYPA) (N-term) mouse monoclonal antibody, clone HIR2, Purified
| Applications | AGG, FC, IHC |
| Reactivities | Human |
Anti-LGR5 mouse mAb, clone OTI2A2, bionylated
| Applications | WB |
| Reactivities | Human, Mouse |
| Conjugation | Biotin |
Loading control antibody sample kit (mouse)
| Applications | WB |
| Reactivities | Human, Monkey, Mouse, Rat, Dog |
IL7 rat monoclonal antibody, clone BVD10-40F6, Purified
| Applications | ELISA |
| Reactivities | Human |
CD61 (ITGB3) mouse monoclonal antibody, clone VIPL2, Aff - Purified
| Applications | FC, IHC, WB |
| Reactivities | Human, Primate |
IP10 (CXCL10) mouse monoclonal antibody, clone 6D4, Biotin
| Applications | ELISA, FC, IF, IHC, WB |
| Reactivities | Human |
| Conjugation | Biotin |
Ly6g rat monoclonal antibody, clone 6D17, Purified
| Applications | FC, IHC |
| Reactivities | Mouse |
OVAL mouse monoclonal antibody, clone 2C6, Purified
| Applications | ELISA |
| Reactivities | Chicken |
Anti-SNAI1 (SNAIL) mouse monoclonal antibody, clone OTI5E12 (formerly 5E12)
| Applications | IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
Special Offer: Get a 15% discount on this product. Use code: “NEURO15".
USD 260.00
2 Weeks
Parathyroid Hormone (PTH) (1-37) mouse monoclonal antibody, clone 77/78, Purified
| Applications | ELISA, IHC |
| Reactivities | Human |
DEFB4B (4-41) mouse monoclonal antibody, clone L12-4C-C2, Purified
| Applications | ELISA, IHC, WB |
| Reactivities | Human |
Tcl1 (TCL1A) mouse monoclonal antibody, clone MRQ-7, Supernatant
| Applications | IHC |
| Reactivities | Human |
Mouse Monoclonal ApoE4 Antibody (4E4)
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 2,060.00
2 Weeks
Staphylococcus aureus (Peptidoglycan) mouse monoclonal antibody, clone 702, Biotin
| Applications | ELISA |
| Conjugation | Biotin |
USD 230.00
2 Weeks
Anti-Remicade(Infliximab) mouse monoclonal antibody, clone 103A8.03
| Applications | ELISA, FN |
| Reactivities | Human |
Syndecan 1 (SDC1) mouse monoclonal antibody, clone B-A38, Azide Free
| Applications | FC, IHC |
| Reactivities | Human |
USD 385.00
5 Days
MITF mouse monoclonal antibody, clone C5, Purified
| Applications | EMSA, IHC, IP, WB |
| Reactivities | Human, Mouse, Rat |
USD 395.00
2 Weeks
Adeno-Associated Virus 5 / AAV5 (intact particle) mouse monoclonal antibody, clone ADK5a, Aff - Purified
| Applications | ELISA, IF, IHC, IP, NEUT |
Carrier-free (BSA/glycerol-free) PKM2 mouse monoclonal antibody, clone OTI12D5 (formerly 12D5)
| Applications | IHC, WB |
| Reactivities | Human |
FSH beta (FSHB) (intact) mouse monoclonal antibody, clone 090-10264, Purified
| Applications | ELISA |
| Reactivities | Human |
Laminin 5 (LAMB3) mouse monoclonal antibody, clone 6F12, Purified
| Applications | ELISA, IHC, WB |
| Reactivities | Human, Rat |
USD 220.00
5 Days
USD 735.00
2 Weeks
D-Dimer mouse monoclonal antibody, clone B2875M (formerly named 15C5), Purified
| Applications | ELISA |
| Reactivities | Human |
USD 479.00
2 Weeks
USD 399.00
In Stock
USD 300.00
2 Weeks
T Cell Receptor (TCR) alpha/beta mouse monoclonal antibody, clone IP26, APC
| Applications | FC |
| Reactivities | Human |
| Conjugation | APC |
Human Kappa Light Chain mouse monoclonal antibody, clone TB28-2, Aff - Purified
| Applications | FC |
| Reactivities | Human |
Melanoma (25-110 kDa) mouse monoclonal antibody, clone NKI/C3, Ascites
| Applications | IHC |
| Reactivities | Human |
Tenascin C (TNC) mouse monoclonal antibody, clone T2H5, Purified
| Applications | ELISA, IHC, IP, WB |
| Reactivities | Human |
Active filters
Category
-
Antibodies
- Primary Antibodies
Clonalities
- Monoclonal
Filter by
Target Symbol
- VSNL1 (271)
- ALK (269)
- KLK8 (253)
- CD4 (244)
- PDCD1 (228)
- ERBB2 (216)
- CD5 (215)
- MAP2K1 (214)
- TP53 (207)
- CDKN2A (183)
- NME1 (170)
- PGR (168)
- ABCB1 (163)
- JUN (157)
- MKI67 (155)
- ERCC1 (153)
- MAP2K3 (151)
- GLI1 (149)
- EGFR (146)
- KRT19 (142)
- PECAM1 (140)
- TG (137)
- CD274 (135)
- CD68 (131)
- CTAG1B (131)
- CTNNB1 (130)
- GADD45G (130)
- LIPG (130)
- CD40 (129)
- HAVCR2 (129)
- NBN (126)
- OTC (125)
- PTPRC (125)
- MSMB (123)
- VIM (123)
- CD99 (118)
- PCNA (113)
- CD80 (112)
- NKX3-1 (112)
- CFI (111)
- PIK3C2A (111)
- AFP (108)
- ADIPOQ (107)
- MDM2 (107)
- NUMB (106)
- EPCAM (104)
- LGALS3 (103)
- CTLA4 (102)
- VWF (102)
- CD8A (99)
- MAPK13 (98)
- MLANA (98)
- CD44 (97)
- CD47 (97)
- CD63 (97)
- L1CAM (96)
- MS4A1 (96)
- TOP2A (96)
- KRT20 (95)
- UBE2E3 (95)
- APP (91)
- SENP2 (90)
- TNFRSF8 (90)
- BTLA (87)
- CD33 (87)
- F13A1 (87)
- NKX2-1 (87)
- PNMT (87)
- CD19 (86)
- TYMS (86)
- KIT (85)
- BCL2 (82)
- CD27 (82)
- MLH1 (82)
- BRAF (81)
- PDCD1LG2 (81)
- MDM4 (80)
- MIEN1 (80)
- CD86 (79)
- CHGA (78)
- TIGIT (78)
- ALDH1L1 (75)
- NCAM1 (75)
- TACC2 (75)
- CD163 (74)
- LGR5 (74)
- FGF21 (73)
- GFAP (73)
- PROCR (71)
- BHLHE41 (70)
- FSHB (70)
- PARVA (70)
- SPG7 (70)
- UBA52 (70)
- AKT1 (69)
- TNFRSF9 (69)
- BCL10 (68)
- ICOS (68)
- CD1C (67)
- FOLH1 (66)
Reactivities
- Human (68932)
- Mouse (39610)
- Rat (37763)
- Monkey (4563)
- Dog (3955)
- Bovine (116)
- Hamster (85)
- Rabbit (85)
- Porcine (80)
- Canine (72)
- Chicken (65)
- SARS-CoV-2 (63)
- Primate (57)
- Pig (41)
- Sheep (39)
- Xenopus (29)
- Zebrafish (29)
- Guinea Pig (27)
- Virus (23)
- Drosophila (21)
- Chimpanzee (18)
- Escherichia coli (18)
- Feline (16)
- Mammalian (16)
- Cow (13)
- Frog (13)
- Goat (12)
- Yeast (12)
- C-term DDK (10)
- Fish (10)
- Macaque (10)
- All Species (9)
- Streptococcus Pyogenes (9)
- Equine (8)
- SARS-CoV (8)
- Saccharomyces cerevisiae (8)
- Baboon (6)
- C. elegans (6)
- Avian (5)
- Horse (5)
- Opossum (5)
- Cynomolgus (4)
- Ferret (4)
- Fruit fly (4)
- HIV (4)
- Insect (4)
- Rhesus Monkey (4)
- Amphibian (3)
- Beluga (3)
- Marmoset (3)
- Plant (3)
- Respiratory Syncytial Virus (3)
- Bacteria (2)
- Dengue virus (2)
- Dictyostelium (2)
- Drosophila melanogaster (2)
- West Nile Virus (2)
- Yellow Fever Virus (2)
- Bacillus Antracis (1)
- Broad (1)
- Carp (1)
- Chlamydomonas (1)
- Fungi (1)
- Helicobacter pylori (1)
- Salmonella Typhimurium (1)
- Spinach (1)
- Squirrel (1)
- Staphylococcus aureus (1)
- Trichinella spiralis (1)
- White Fly (1)
Applications
- WB (69563)
- IHC (35212)
- FC (22931)
- IF (21052)
- ELISA (6355)
- IP (4015)
- LMNX (1099)
- FN (650)
- 10k-ChIP (435)
- Assay (199)
- NEUT (178)
- R (145)
- Bl (92)
- CT (76)
- SISCAPA (35)
- ChIP (33)
- LF (33)
- EM (27)
- Neutralize (25)
- Inhib (24)
- AGG (21)
- ICC (12)
- RNAi (11)
- ID (9)
- ISH (6)
- Dot (5)
- Elispot (5)
- PLA (5)
- EMSA (4)
- MC (3)
- SB (3)
- CLIA (2)
- E (2)
- EIA (2)
- Func (2)
- Labeling (2)
- P (2)
- C (1)
- H (1)
- IA (1)
Antibody Hosts
Isotypes
- IgG1 (52289)
- IgG2a (13504)
- IgG2b (11302)
- IgG (1548)
- IgG1, kappa (570)
- IgM (451)
- IgG, kappa (372)
- IgG3 (348)
- IgG2a, kappa (169)
- IgG2 (117)
- IgG2b, kappa (104)
- IgG2c (44)
- IgG1, lambda (36)
- IgM, kappa (22)
- Fab fragment, kappa (19)
- IgG3, kappa (16)
- IgG4 (13)
- IgA (11)
- IgG2a, lambda (11)
- IgG1-Fc Fusion (8)
- IgG2b, lambda (6)
- cocktail (6)
- Fab fragment, lambda (4)
- IgA-Fc Fusion (4)
- IgE (4)
- IgG-Fc Fusion (4)
- IgM-Fc Fusion (4)
- Ig (2)
- IgD (2)
- IgG1/IgG2b (2)
- IgG2, kappa (2)
- scFv (2)
- IgA, kappa (1)
- IgG fraction (1)
- IgG/IgM (1)
- IgG1/IgK (1)
- IgG1/IgM (1)
- IgG12b (1)
- IgG2, alpha (1)
- IgG3/IgG1 (1)
Conjugates
- Unconjugated (44879)
- Biotin (13421)
- HRP (12410)
- FITC (973)
- PE (766)
- APC (160)
- Alexa Fluor 488 (59)
- Alexa Fluor 647 (54)
- Alexa Fluor 546 (52)
- PerCP (34)
- His Tag (23)
- PE-Cy7 (12)
- AP (9)
- APC-Cy7 (8)
- Cy5 (7)
- PE-Cy5.5 (7)
- Agarose (6)
- DyLight 488 (6)
- PE-DL594 (4)
- PE-TXRD (4)
- APC-Cy5.5 (3)
- PerCP-Cy5.5 (3)
- Sepharose (3)
- FLMA (2)
- TAMRA (2)
- TRITC (2)
- BIMA (1)
- DyLight 550 (1)
- DyLight 633 (1)
- Magnetic Beads (1)
- PE-Cy5 (1)
- Texas Red (1)
Carrier-free
Knockout (KO) Validation
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (94)
- This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. (44)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (36)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (27)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (23)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (20)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (18)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human Fab format, for improved compatibility with existing reagents, assays and techniques. (17)
- Phospho-specific (16)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (15)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (15)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (14)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (14)
- This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. (12)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (8)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. (8)
- This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (8)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (6)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (6)
- This full-length, reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (6)
- This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (6)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (6)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric mouse antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (4)
- This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (4)
- Modification (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG2 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human scFv format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2b format, for improved compatibility with existing reagents, assays and techniques. (3)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (3)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric hamster (Armenian) antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This constant region of this antibody has been modified to bind to Protein A, allowing highly-specific purification of this antibody by Protein A-affinity column. (2)
- This full-length, chimeric mouse antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric murine antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Armenian Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Armenian Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This full-length, chimeric mouse antibody was made using the variable domain sequences of the original Chicken scFv format, for improved compatibility with existing reagents, assays and techniques. (1)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Chicken scFv format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric antibody created to reduce immunogenicity during in vivo applications. (1)
- This is a chimeric human antibody, based on the original mouse IgG2a format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric mouse antibody, based on the original hamster IgG format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric mouse antibody, based on the original rat IgG2b format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric recombinant Fab fragment created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. (1)
- This is a recombinant chimeric Fab fragment created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. (1)
- This is a reformatted human IgG1 antibody based on the therapeutic Fab fragment. NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (1)
- This is a reformatted mouse IgG1 antibody, based on the original mouse IgG2a format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted antibody was made using the variable domain sequences of the original mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted antibody was made using the variable domain sequences of the original rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original mouse scFv format for improved compatibility with existing reagents, assays and techniques. (1)
Assay Types
Assay Platforms
Families
- Druggable Genome (39901)
- Transmembrane (13551)
- Transcription Factors (10994)
- Secreted Protein (6545)
- ES Cell Differentiation/IPS (5775)
- Protein Kinase (4464)
- Protease (3094)
- Stem cell - Pluripotency (2583)
- Adult stem cells (1520)
- Embryonic stem cells (949)
- Nuclear Hormone Receptor (947)
- Phosphatase (738)
- Cancer stem cells (663)
- Induced pluripotent stem cells (503)
- Stem cell relevant signaling - DSL/Notch pathway (423)
- Stem cell relevant signaling - JAK/STAT signaling pathway (362)
- P450 (309)
- Ion Channels: Other (304)
- GPCR (210)
- Stem cell relevant signaling - TGFb/BMP signaling pathway (173)
- Stem cell relevant signaling - Wnt Signaling pathway (75)
- Ion Channels: Potassium (50)
- Ion Channels: Transient receptor potential (37)
- Ion Channels: Cys-loop Receptors (28)
- Ion Channels: Sodium (9)
- Ion Channels: Calcium (4)
- Ion Channels: Glutamate Receptors (2)
- Ion Channels: Cyclic nucleotide gated (1)
Pathways
- Metabolic pathways (6432)
- Pathways in cancer (4996)
- MAPK signaling pathway (3184)
- Focal adhesion (2595)
- Cell adhesion molecules (CAMs) (2528)
- Prostate cancer (2438)
- T cell receptor signaling pathway (2414)
- Cytokine-cytokine receptor interaction (2254)
- Hematopoietic cell lineage (2023)
- Colorectal cancer (2017)
- Toll-like receptor signaling pathway (1960)
- Neurotrophin signaling pathway (1953)
- Melanoma (1919)
- Pancreatic cancer (1863)
- ErbB signaling pathway (1841)
- Bladder cancer (1815)
- Glioma (1764)
- Endometrial cancer (1729)
- Non-small cell lung cancer (1718)
- Regulation of actin cytoskeleton (1710)
- Chronic myeloid leukemia (1683)
- Cell cycle (1639)
- B cell receptor signaling pathway (1595)
- Progesterone-mediated oocyte maturation (1592)
- Insulin signaling pathway (1457)
- Jak-STAT signaling pathway (1427)
- Endocytosis (1407)
- GnRH signaling pathway (1383)
- Fc epsilon RI signaling pathway (1364)
- Apoptosis (1304)
- Natural killer cell mediated cytotoxicity (1293)
- Renal cell carcinoma (1264)
- Acute myeloid leukemia (1244)
- p53 signaling pathway (1185)
- Leukocyte transendothelial migration (1168)
- Wnt signaling pathway (1168)
- Chemokine signaling pathway (1166)
- Small cell lung cancer (1122)
- Purine metabolism (1105)
- VEGF signaling pathway (1089)
- Fc gamma R-mediated phagocytosis (1087)
- Alzheimer's disease (1073)
- Thyroid cancer (1038)
- Gap junction (1030)
- Adherens junction (1008)
- Oocyte meiosis (950)
- Amyotrophic lateral sclerosis (ALS) (949)
- Ubiquitin mediated proteolysis (932)
- Primary immunodeficiency (926)
- Pyrimidine metabolism (910)
- Huntington's disease (896)
- Melanogenesis (860)
- Complement and coagulation cascades (832)
- Epithelial cell signaling in Helicobacter pylori infection (822)
- Calcium signaling pathway (818)
- Systemic lupus erythematosus (775)
- Adipocytokine signaling pathway (771)
- Type II diabetes mellitus (767)
- mTOR signaling pathway (747)
- Autoimmune thyroid disease (721)
- Long-term depression (701)
- Antigen processing and presentation (699)
- Axon guidance (683)
- Basal cell carcinoma (678)
- Long-term potentiation (667)
- Glycolysis / Gluconeogenesis (658)
- Tight junction (657)
- NOD-like receptor signaling pathway (638)
- Pathogenic Escherichia coli infection (630)
- Vascular smooth muscle contraction (622)
- Arginine and proline metabolism (617)
- RIG-I-like receptor signaling pathway (614)
- Viral myocarditis (610)
- Lysosome (589)
- Prion diseases (579)
- Allograft rejection (578)
- ECM-receptor interaction (571)
- Parkinson's disease (558)
- TGF-beta signaling pathway (541)
- Type I diabetes mellitus (540)
- Nucleotide excision repair (534)
- Dorso-ventral axis formation (517)
- Valine (487)
- Hedgehog signaling pathway (477)
- leucine and isoleucine degradation (476)
- Graft-versus-host disease (475)
- Oxidative phosphorylation (471)
- Hypertrophic cardiomyopathy (HCM) (463)
- Proteasome (447)
- Dilated cardiomyopathy (435)
- PPAR signaling pathway (423)
- Glycerolipid metabolism (416)
- Cytosolic DNA-sensing pathway (414)
- Tryptophan metabolism (409)
- RNA degradation (397)
- Lysine degradation (395)
- Phosphatidylinositol signaling system (394)
- Arachidonic acid metabolism (380)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (379)
- Neuroactive ligand-receptor interaction (371)
- Propanoate metabolism (371)
- Pyruvate metabolism (367)
- Drug metabolism - cytochrome P450 (366)
- Metabolism of xenobiotics by cytochrome P450 (362)
- Spliceosome (358)
- One carbon pool by folate (356)
- Inositol phosphate metabolism (353)
- Glutathione metabolism (348)
- Fatty acid metabolism (347)
- Mismatch repair (337)
- Alanine (335)
- aspartate and glutamate metabolism (335)
- Histidine metabolism (331)
- DNA replication (323)
- Tyrosine metabolism (313)
- Notch signaling pathway (308)
- Butanoate metabolism (287)
- Base excision repair (280)
- Glycine (274)
- serine and threonine metabolism (274)
- beta-Alanine metabolism (272)
- Asthma (250)
- Renin-angiotensin system (246)
- ABC transporters (239)
- Maturity onset diabetes of the young (238)
- Drug metabolism - other enzymes (236)
- Vibrio cholerae infection (236)
- Fructose and mannose metabolism (232)
- Cardiac muscle contraction (231)
- Retinol metabolism (218)
- Cysteine and methionine metabolism (215)
- Circadian rhythm - mammal (211)
- Amino sugar and nucleotide sugar metabolism (203)
- Homologous recombination (201)
- Starch and sucrose metabolism (200)
- Nicotinate and nicotinamide metabolism (180)
- Linoleic acid metabolism (174)
- SNARE interactions in vesicular transport (169)
- Citrate cycle (TCA cycle) (165)
- Pentose phosphate pathway (165)
- Regulation of autophagy (157)
- Glycerophospholipid metabolism (145)
- Terpenoid backbone biosynthesis (145)
- RNA polymerase (138)
- Porphyrin and chlorophyll metabolism (137)
- Sphingolipid metabolism (134)
- Aminoacyl-tRNA biosynthesis (130)
- Folate biosynthesis (130)
- Sulfur metabolism (130)
- Nitrogen metabolism (125)
- Ribosome (124)
- Galactose metabolism (118)
- Methane metabolism (116)
- Ascorbate and aldarate metabolism (114)
- Other glycan degradation (113)
- Caffeine metabolism (110)
- Fatty acid elongation in mitochondria (109)
- Primary bile acid biosynthesis (104)
- N-Glycan biosynthesis (103)
- Glyoxylate and dicarboxylate metabolism (91)
- Non-homologous end-joining (91)
- Selenoamino acid metabolism (91)
- Phenylalanine metabolism (81)
- Basal transcription factors (79)
- Cyanoamino acid metabolism (77)
- Synthesis and degradation of ketone bodies (74)
- Androgen and estrogen metabolism (72)
- Olfactory transduction (72)
- Ether lipid metabolism (70)
- Thiamine metabolism (70)
- Limonene and pinene degradation (64)
- Glycosaminoglycan degradation (55)
- Taste transduction (55)
- Pantothenate and CoA biosynthesis (45)
- Biosynthesis of unsaturated fatty acids (40)
- C21-Steroid hormone metabolism (40)
- Riboflavin metabolism (35)
- Fatty acid biosynthesis (33)
- Vitamin B6 metabolism (32)
- Glycosphingolipid biosynthesis - lacto and neolacto series (31)
- Keratan sulfate biosynthesis (30)
- alpha-Linolenic acid metabolism (30)
- Pentose and glucuronate interconversions (29)
- Glycosphingolipid biosynthesis - ganglio series (25)
- Steroid biosynthesis (21)
- Glycosphingolipid biosynthesis - globo series (20)
- leucine and isoleucine biosynthesis (18)
- Taurine and hypotaurine metabolism (16)
- D-Glutamine and D-glutamate metabolism (15)
- Phenylalanine (11)
- tyrosine and tryptophan biosynthesis (11)
- O-Glycan biosynthesis (10)
- Protein export (10)
- Biotin metabolism (5)
- Ubiquinone and other terpenoid-quinone biosynthesis (5)
- Chondroitin sulfate biosynthesis (2)
- Heparan sulfate biosynthesis (2)